Management Change/Compensation (Form 8-K)

Resignation of Chief Financial Officer

On April 8, 2026, Matthew Gall notified Kalaris Therapeutics, Inc. (the "Company") of his decision to resign as the Chief Financial Officer of the Company, effective April 14, 2026 (the "Separation Date").

Appointment of Principal Financial Officer

As a result of Mr. Gall's resignation, Brett Hagen, the Company's Chief Accounting Officer and principal accounting officer, will also serve as the Company's principal financial officer, effective as of the Separation Date.

Brett Hagen, 53, has served as the Company's Chief Accounting Officer since January 2019. Prior to joining the Company, Mr. Hagen served as senior director finance and accounting at Eloxx Pharmaceuticals, Inc. from February 2018 to August 2018. Prior to that, Mr. Hagen served as vice president, finance and controller at Proteostasis Therapeutics, Inc. from May 2016 to December 2017. From July 2014 to May 2016, Mr. Hagen served as controller at BIND Therapeutics, Inc. Mr. Hagen received his B.A. from the University of Minnesota, a graduate degree in accounting from Wright State University and a graduate degree in finance from Suffolk University.

Mr. Hagen does not have a family relationship with any of the Company's officers or directors and has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

There have been no changes to Mr. Hagen's compensatory plans or arrangements in connection with his appointment described herein.